Solian: Atypical Antipsychotic for Schizophrenia Symptom Control
Solian
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $3.23 | $97.00 (0%) | 🛒 Add to cart |
| 60 | $2.97 | $194.00 $178.00 (8%) | 🛒 Add to cart |
| 90 | $2.88 | $291.00 $259.00 (11%) | 🛒 Add to cart |
| 120 | $2.84 | $388.00 $341.00 (12%) | 🛒 Add to cart |
| 180 | $2.79 | $582.00 $502.00 (14%) | 🛒 Add to cart |
| 270 | $2.76
Best per pill | $873.00 $745.00 (15%) | 🛒 Add to cart |
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.97 | $89.00 (0%) | 🛒 Add to cart |
| 60 | $2.72 | $178.00 $163.00 (8%) | 🛒 Add to cart |
| 90 | $2.63 | $267.00 $237.00 (11%) | 🛒 Add to cart |
| 120 | $2.59 | $356.00 $311.00 (13%) | 🛒 Add to cart |
| 180 | $2.54 | $534.00 $458.00 (14%) | 🛒 Add to cart |
| 270 | $2.52
Best per pill | $801.00 $681.00 (15%) | 🛒 Add to cart |
Synonyms | |||
Solian (amisulpride) is an atypical antipsychotic medication indicated for the treatment of schizophrenia in adults. It functions primarily as a dopamine D2 and D3 receptor antagonist, with selective action on limbic rather than striatal regions, which contributes to its efficacy in managing positive symptoms (such as hallucinations and delusions) while exhibiting a lower propensity for extrapyramidal side effects compared to conventional antipsychotics. Clinical evidence supports its use in both acute psychotic episodes and maintenance therapy, offering a favorable balance between symptom control and tolerability for many patients. It is available in tablet form and requires prescription and supervision by a healthcare professional specializing in psychiatric disorders.
Features
- Active ingredient: Amisulpride
- Drug class: Atypical antipsychotic
- Available strengths: 50 mg, 100 mg, 200 mg, 400 mg film-coated tablets
- Selective dopamine D2/D3 receptor antagonist
- High oral bioavailability (~48%)
- Elimination half-life of approximately 12 hours
- Excreted largely unchanged in urine
Benefits
- Effective reduction of positive symptoms of schizophrenia, including hallucinations and delusions
- Lower incidence of extrapyramidal symptoms compared to typical antipsychotics
- Potential improvement in negative symptoms (e.g., social withdrawal, apathy) at lower doses
- Once-daily dosing convenience for maintenance therapy (depending on dosage)
- Generally well-tolerated profile with a lower risk of sedation than some other antipsychotics
- May improve overall patient functioning and quality of life when used as part of a comprehensive treatment plan
Common use
Solian is primarily prescribed for the management of schizophrenia in adults. It is used both in the acute phase treatment of psychotic episodes and as maintenance therapy to prevent relapse. In some jurisdictions, it may also be approved for the treatment of dysthymia (chronic mild depression), though this use is not universal. Treatment is always initiated and monitored by a psychiatrist, often in conjunction with psychosocial interventions.
Dosage and direction
Dosage must be individualized based on symptom profile, patient response, and tolerability. For positive symptoms, the usual dosage range is 400–800 mg/day, administered orally in two divided doses (though once-daily dosing may be possible for some patients during maintenance). For predominant negative symptoms, lower doses (50–300 mg/day) are often used. The starting dose is typically 200–400 mg/day, which may be gradually adjusted. Tablets should be swallowed whole with water, before meals. Dosage adjustment is necessary in patients with renal impairment.
Precautions
Use with caution in elderly patients, who may be more susceptible to side effects. Cardiovascular monitoring is advised due to potential QT interval prolongation. Regular clinical assessments are required to monitor for extrapyramidal symptoms, hyperprolactinemia, and weight gain. Solian may impair alertness; patients should be cautioned about driving or operating machinery. Alcohol should be avoided. Not recommended during pregnancy unless clearly necessary; use during breastfeeding is not advised. Renal function should be assessed before and during treatment.
Contraindications
Hypersensitivity to amisulpride or any excipients; concomitant use with levodopa; pheochromocytoma; prolactin-dependent tumors; severe renal impairment (creatinine clearance <30 mL/min); history of torsades de pointes or congenital long QT syndrome; combination with other drugs known to prolong QT interval.
Possible side effects
Common: Hyperprolactinemia (which may lead to galactorrhea, gynecomastia, amenorrhea), insomnia, anxiety, agitation. Less common: Extrapyramidal symptoms (e.g., akathisia, dystonia), weight gain, constipation, dry mouth, blurred vision. QT prolongation on ECG may occur. Rare but serious: Neuroleptic malignant syndrome, tardive dyskinesia, seizures, venous thromboembolism.
Drug interaction
Potentially serious interactions with: Other antipsychotics, antiarrhythmics (e.g., amiodarone, sotalol), certain antibiotics (e.g., erythromycin), antidepressants, lithium, and other drugs that prolong QT interval or cause electrolyte imbalance. Concomitant use with dopamine agonists (e.g., levodopa) is contraindicated. Caution with CNS depressants (alcohol, benzodiazepines).
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next dose. In that case, skip the missed dose and resume the regular schedule. Do not double the dose to make up for a missed one.
Overdose
Symptoms may include sedation, coma, hypotension, extrapyramidal symptoms, and QT prolongation. Management is supportive; there is no specific antidote. Gastric lavage may be considered if presented early. ECG monitoring is essential. Contact a poison control center or emergency department immediately.
Storage
Store below 30°C (86°F) in the original packaging to protect from light and moisture. Keep out of reach of children. Do not use after the expiration date.
Disclaimer
This information is for educational purposes and does not replace professional medical advice. Always consult a qualified healthcare provider for diagnosis, treatment decisions, and personalized dosage guidance. Do not initiate or discontinue Solian without medical supervision.
Reviews
Clinical studies and meta-analyses consistently demonstrate the efficacy of amisulpride in the treatment of schizophrenia, with particular strength in managing positive symptoms. It is often noted for its relatively favorable side effect profile regarding extrapyramidal symptoms, though hyperprolactinemia remains a significant concern. Many experts consider it a valuable option within the atypical antipsychotic class, especially when tailored to individual patient symptoms and tolerance. Long-term adherence and outcomes are generally positive when used within a structured therapeutic alliance.